5 Key Takeaways

• 1

  The FDA approved Genentech's Susvimo for diabetic retinopathy, expanding its use beyond neovascular age-related macular degeneration and diabetic macular edema.

• 2

  Susvimo is the first continuous delivery system for diabetic retinopathy, requiring only one treatment every nine months.

• 3

  The drug delivers ranibizumab through a surgically implanted, refillable ocular device, reducing the need for frequent injections.

• 4

  Approval was based on the phase 3 PAVILION study, which showed significant improvement in DR severity with Susvimo compared to observation.

• 5

  Susvimo is now available to US retina specialists and patients who have previously responded to anti-VEGF injections, with support programs for access.